During the last session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares were 1.28 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stock’s price was $8.50, reflecting an intraday loss of -7.81% or -$0.72. The 52-week high for the GLUE share is $12.40, that puts it down -45.88 from that peak though still a striking 65.76% gain since the share price plummeted to a 52-week low of $2.91. The company’s market capitalization is $521.67M, and the average intraday trading volume over the past 10 days was 10.48 million shares, and the average trade volume was 1.92 million shares over the past three months.
Monte Rosa Therapeutics Inc (GLUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. GLUE has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.49.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Monte Rosa Therapeutics Inc (GLUE) registered a -7.81% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -7.81% in intraday trading to $8.50, hitting a weekly high. The stock’s 5-day price performance is 74.54%, and it has moved by 57.70% in 30 days. Based on these gigs, the overall price performance for the year is 150.00%. The short interest in Monte Rosa Therapeutics Inc (NASDAQ:GLUE) is 5.23 million shares and it means that shorts have 8.36 day(s) to cover.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Statistics show that Monte Rosa Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Monte Rosa Therapeutics Inc (GLUE) shares have gone up 51.79% during the last six months, with a year-to-date growth rate more than the industry average at 30.42% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 30.00% this quarter and then jump 20.70% in the quarter after that.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.62M as predicted by 7 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 2.82M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -96.71%. While earnings are projected to return 28.94% in 2024.
GLUE Dividends
Monte Rosa Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Monte Rosa Therapeutics Inc insiders own 0.71% of total outstanding shares while institutional holders control 86.75%, with the float percentage being 87.36%. NEA MANAGEMENT COMPANY, LLC is the largest shareholder of the company, while 115.0 institutions own stock in it. As of 2024-06-30, the company held over 7.69 million shares (or 12.7872% of all shares), a total value of $28.77 million in shares.
The next largest institutional holding, with 5.98 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 9.9368% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.36 million.
